Behind the scenes in Eliquis drama

| | Cardiovascular Business | Heart Rhythm

The June issue of Pharmaceuticals Monthly explores the delay in the approval of apixaban (Eliquis) by the FDA. “Apixaban shows how a review that seems, on its face, like it should be a quick and clean affair can become derailed by issues that, but for the agency’s own public disclosures post-approval, would never see the light of day,” according to the article.

Eliquis approval delayed by fraud, dispensing errors in pivotal trial

Related Content

LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Eko Health’s AI platform for digital stethoscopes granted new CPT code
Predicting sudden cardiac death after a heart attack may be impossible—for now
Concomitant ablation surgery during heart operations boosts long-term survival
Johnson & Johnson MedTech gains FDA approval for Varipulse PFA system
Boston Scientific agrees to acquire AFib ablation company

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."